GCP and Quality in "Regulation (EU) 536/2014 on clinical trials on medicinal products for human use and repealing Directive 2001/20/EU

被引:0
|
作者
Filibeck, Umberto [1 ]
Sanzi, Eleonora [1 ]
机构
[1] Univ Roma Tor Vergata, Rome, Italy
关键词
EU Regulation No 536/2014; Directive; 2001/20/EC; Good Clinical Practice; Quality; Clinical Trials legislation;
D O I
10.1016/j.microc.2017.08.003
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Among the several new provisions foreseen by the EU Regulation (R) 2014/536 on Clinical Trials (CTs) repealing Directive (D) 2001/20/EC, this article focuses on the identification of possible critical points leading to potential incongruences regarding Good Clinical Practice (GCP). EU D foresees the obligation to be in compliance with GCP detailed guidelines, while the R foresees the obligation to be in compliance only with the GCP principles. Many of the GCP detailed aspects have been transposed in the R and the R provides to be in compliance with GCP quality standards. Nevertheless, other GCP aspects, which have direct or indirect ethical implication in CTs, will not be mandatory in the EU. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:40 / 42
页数:3
相关论文
共 50 条